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Activation of the peroxynitrite-poly(adenosine
diphosphate-ribose) polymerase pathway during
neointima proliferation: A new target to prevent
restenosis after endarterectomy
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Objective: In a rat model of endarterectomy, we investigated the potential role of the peroxynitrite-poly(adenosine
diphosphate[ADP]-ribose) polymerase (PARP) pathway in neointima formation and the effect of pharmacologic
inhibition of PARP on vascular remodeling.
Methods: Carotid endarterectomy was performed in male Sprague-Dawley rats by incision of the left carotid artery with
removal of intima. Three groups were studied: sham-operated rats (n  10), control rats with endarterectomy (n  10)
or rats with endarterectomy treated with the PARP inhibitor, INO-1001 (5 mg/kg daily) postoperatively (n10). After
21 days, neointima formation and vascular remodeling were assessed.
Results: Immunohistochemistry analysis demonstrated activation of the peroxynitrite-PARP pathway with significant
staining for nitrotyrosine, poly(ADP-ribose), and nuclear translocation of apoptosis-inducing factor (AIF) in the
neointima of the control group. Treatment with INO-1001 significantly reduced the neointima area (0.024 mm2 0.019
mm2 vs 0.089 mm2  0.033 mm2 in the control group), the neointima/media thickness ratio (0.81  0.05 vs 2.76 
1.57 in the control group), and the inflammation score (0.1  0.07 vs 0.3  0.12 in the control group) after
endarterectomy.
Conclusions: Pharmacologic inhibition of PARP with INO-1001 may be a new concept to prevent neointimal hyperplasia
after endarterectomy. (J Vasc Surg 2006;43:824-30.)
Clinical Relevance: Neointimal hyperplasia is a proliferative response to an arterial injury and a significant cause of bypass
graft and angioplasty failure. Although there is growing evidence that reactive oxygen species and oxidative damage play
an important role in restenosis, the molecular physiologic mechanism underlying the oxidative stress hypothesis is not
fully understood. In the present study, we demonstrated that consistent with nitrosative stress, poly(adenosine
diphosphate-ribose) polymerase (PARP) activation and apoptosis-inducing factor translocation were significantly
increased in the neointima after endarterectomy. Neointima formation and inflammatory response after endarterectomy
were attenuated by treatment with the PARP inhibitor INO-1001. PARP inhibition, therefore, may be a therapeutic
strategy for prevention of restenosis after surgical vessel reconstruction.Carotid endarterectomy is the standard treatment of
severe carotid stenosis in symptomatic and asymptomatic
patients.1,2 A recent analysis identified a 7.7% failure rate
during a median follow-up of 5.9 years.3 Coronary endar-
terectomy is a treatment option for patients with end-stage
coronary artery disease who are not suitable for conven-
tional revascularization strategies. The patency rate of end-
arterectomized coronary arteries (72%  11% at 30.4
months) is lower compared with those after carotid endar-
terectomy.4 Despite technical problems, the main causes
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824for restenosis after surgical vessel reconstruction are neoin-
timal hyperplasia, recurrent atherosclerosis, and arterial
wall remodeling.
Evidence is growing that reactive oxygen and nitrogen
species play a very important role in the pathogenesis of
various cardiovascular diseases such as atherosclerosis, hy-
pertension, diabetic cardiovascular complications, and re-
stenosis after angioplasty.5-8 Few studies, however, have
addressed the underlying mechanism of the oxidative hy-
pothesis for restenosis. Pathophysiologic states such as in-
flammation, circulatory shock, and ischemia-reperfusion
generate free radical and oxidant species, especially per-
oxynitrite, which in turn produce DNA injury and activate
poly(adenosine diphosphate [ADP]-ribose) polymerase
(PARP), a nuclear enzyme that mediates the cellular re-
sponse.9
PARP contributes to the pathogenesis of various car-
diovascular diseases, including arteriosclerosis, myocardial
infarction, and diabetic endothelial dysfunction.10-12 Re-
cent studies suggest that in addition to DNA damage
repair, PARP has several other important effects, including
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that eventually leads to cell dysfunction and cell death via
the necrotic route.9 PARP also participates in the inflam-
matory response by regulating inflammatory cell infiltra-
tion.9 We recently showed that PARP regulates the release
and nuclear translocation of the mitochondrial cell death
factor, apoptosis-inducing factor (AIF), in cardiac myo-
cytes during oxidant stress.13 AIF is the central factor of the
caspase-independent activation of apoptosis.13
Because nitrosative stress, activation of PARP, and subse-
quently AIF play a central role in various forms of vascular
dysfunction and injury, we investigated in a rat model of
endarterectomy the potential role of the peroxynitrite-
PARP pathway in inflammatory response and apoptosis
induction during neointimal proliferation. We also studied
whether inhibition of the peroxynitrite-PARP pathway
with the ultrapotent PARP inhibitor INO–100114 may
affect the development of neointimal hyperplasia after end-
arterectomy.
METHODS
Experimental model. The protocol was approved by
the Regional Ethical Committee for Laboratory Animal
Use and conformed with the Guide for the Care and Use of
Laboratory Animals published by the United States Na-
tional Institutes of Health (NIH Publication No. 85-23,
revised 1996). Twenty male Sprague-Dawley rats (350 to
400 g body weight) underwent left carotid endarterectomy
with removal of intima, and 10 rats had a sham operation.
After adequate anesthesia with an intraperitoneal injection
of ketamine hydrochloride (100 mg/kg) and xylazine hy-
drochloride (5 mg/kg), the left common carotid artery was
exposed under a dissecting microscope via a midline cervi-
cal incision.
Carotid endarterectomy. A longitudinal arteriotomy
was made with a corneal blade and extended to 6 mm with
microscissors after clamping of the left common carotid
artery. To denude the endothelium, a sterile cotton-tipped
applicator immersed in saponin (0.1%) was rubbed on the
inner vessel surface. This chemical skinning technique was
used to preserve vascular smooth muscle function postop-
eratively.15 The arteriotomy was closed with a running
10-0 Ethilon monofilament nylon suture (Ethicon, Inc,
Somerville, NJ).
Experimental groups. Animals were divided into
three groups: (1) sham operated animals (n 10) in which
the carotid artery was not incised; (2) control carotid
endarterectomy group (n  10) treated with the vehicle
intraperitoneally (1 mL glucose 5%/d) and (3) PARP
inhibitor-treated group (n  10) that received the PARP
inhibitor INO-1001 (5 mg/kg daily, intraperitoneally)
dissolved in 1 mL of 5% glucose. This dose was chosen, as it
is common for rodents in other experimental set-ups.14
After 21 days, the operated and the contralateral ca-
rotid arteries were perfusion-fixed and harvested. First, the
inferior vena cava was transected and the abdominal aorta
was cannulated. Normal saline solution was infused at 100
mm Hg until the vena cava effluent ran clear, and then asolution of 4% formaldehyde was infused at a constant
pressure of 100 mm Hg in an equal volume to the saline
infusion (200 mL) to complete the perfusion-fixation pro-
cess.
Histology and immunohistochemistry analysis.
Morphometry was performed in three hematoxylin-eosin
stained cross-sections of each animal (proximal, mid, and
distal region of the operated vessel segment) by using
computer-aided planimetry (Q-Win, Leica, Wetzlar, Ger-
many). Luminal, intimal, and medial dimensions were
computed using the internal and external elastic laminae as
delimeters. The inflammatory response in these cross-
sections was scored independently by two pathologists
blinded to the study protocol as follows: 0, no inflamma-
tory cells present; 1, light lymphohistiocytic infiltrate; 2,
moderate-to-dense localized cellular aggregates; and 3,
dense lymphohistiocytic cell infiltration. Inter-rater vari-
ability was low, and consistent inflammatory scores were
obtained.
Immunohistochemistry analysis was done in seven rep-
resentative cross-sections of each animal to test the PARP
activity, the enzymatic product of PARP, poly(ADP-
ribose) (PAR) was determined. Detection of PAR and AIF
was performed as previously described.10 Primary antibod-
ies used for the stainings were mouse monoclonal antipoly-
(ADP-ribose) antibody (Calbiochem, San Diego, Calif)
and rabbit polyclonal anti-AIF antibody (Chemicon Inter-
national, Temecula, Calif).
Peroxynitrite has very short lifetime, therefore per-
oxynitrite generation is usually characterized by nitroty-
rosine (NT), a product of the reaction of peroxynitrite and
tyrosine that is called a “footprint” of peroxynitrite gener-
ation. Immunohistochemical staining for NT was per-
formed as previously described.12 The primary antibody
was rabbit polyclonal anti-NT antibody (Upstate Biotech-
nology, Lake Placid, NY).
As marker for neointima formation, von Willebrand
factor (vWF) was used.16 The primary antibody for vWF
was polyclonal goat antibody (dilution 1:25) (Santa Cruz
Biotechnology, Santa Cruz, Calif) using the avidin biotin
method. For evaluation of inflammatory response, C-reactive
protein (CRP), with polyclonal sheep as the primary anti-
body (dilution 1:200) (Biotrend, Cologne, Germany), and
transforming growth factor 1 (TGF-1) were used. The
primary antibody for TGF-1 was rabbit polyclonal immu-
noglobulin G (dilution 1:100) (Santa Cruz Biotechnol-
ogy). Additionally, staining for tumor necrosis factor-
(TNF-) was performed with monoclonal mouse as the pri-
mary antibody (dilution 1:50) (Santa Cruz Biotechnology).
Immunohistochemical stainings were evaluated by us-
ing the COLIM software package (Pictron Ltd, Budapest,
Hungary). A digital camera was used to input microscopic
pictures from a low-power (16-40) magnification of the
whole section and a high-power (400) examination of 20
adjacent fields. First, positively stained areas were separated
from each other and from the background by the intensity
of different colors in the specimen. The colors were mea-
sured by using densitometry and put in five color classes:
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positively stained areas. The measured intensity was used to
couple the color classes with score values as follows: 0, no
positive staining; 1 to 3, increasing degrees of intermediate
staining; and 4, extensive staining. The program automat-
ically measured the area of the objects in each class in each
field, assigned an area score (1,10% positive cells; 2, 11%
to 50% positive cells; 3, 51% to 80% positive cells, 4,80%
positive cells), and calculated an average score for the whole
picture (intensity score multiplied by area score). Finally,
each specimen was characterized with the average of 20
adjacent fields.
Statistical analysis. Values are expressed as mean 
SD. Statistical comparisons were determined by analysis of
variance followed by an unpaired Student’s t test with the
Bonferroni correction for multiple comparisons. For ordi-
nal data, the Kruskal-Wallis test was use for comparisons
between groups. P .05 was considered statistically signif-
icant.
RESULTS
The examined contralateral arteries of all groups
showed normal morphologic structure and a normal im-
munohistochemical profile, which also indicates that treat-
ment with INO-1001 had no effect on vessel wall structure
under physiologic conditions.
Arterial remodeling and inflammatory response
after endarterectomy and treatment with the PARP
inhibitor INO-1001. Three weeks after endarterectomy,
a neointima was found in the control group that was
Fig 1. Morphometric results and representative histologi
eosin). A, Neointima/media thickness ratio in the differ
sham; †P .05 vs control.B, Sham group.C,Control gr
neointima formation after treatment with INO-1001.significantly different from the sham and INO-1001-treated groups (Fig 1). A maximal neointima thickness of
0.23 mm was measured in the control group. After treat-
ment with INO-1001, significant reduction of neointima
area and neointima to media thickness ratio was observed,
with a maximal neointima thickness of 0.08 mm (Table I).
Neointima formation was confirmed by detection of
vWF, which was significantly elevated in the intima of the
control group (Table II). Parallel to the extent of intimal
thickening during neointima formation, significantly more
immunoreactive TGF-1 was found in the injured ves-
sels, whereas TGF-1 content in the intima of the PARP
inhibitor-treated group was reduced to a level seen in the
sham group (Table II).
A significant inflammation in the vessel wall was found
s-sections of the different treatment groups (hematoxylin-
roups. Values are expressed as mean  SD. P  .05 vs
ith massive neointima proliferation.D, Significantly less
Table I. The effects of treatment with INO-1001 on
vessel wall dimensions
Sham
(n  10)
Control
(n  10)
INO
(n  10)
Neointima area
(mm2) 0.00  0.00 0.09  0.03* 0.02  0.02†
Media area (mm2) 0.06  0.02 0.07  0.04 0.13  0.04
Neointima/media
area ratio 0.00  0.00 0.91  0.60* 0.21  0.19†
Adventitia area
(mm2) 0.17  0.05 0.18  0.16 0.13  0.05
Lumen area (mm2) 0.28  0.09 0.23  0.16 0.26  0.07
Data are expressed as means  SD
*P  .05 vs sham,
†P  .05 vs. control.c cros
ent g
oup win the control group, but in the PARP inhibitor-treated
cont
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(Table II). Corresponding to the inflammatory response
with leukocyte infiltration, there was significantly more
deposition of CRP in the neointima of the control group
compared with sham-operated animals and a trend to re-
duced CRP content in the group treated with INO-1001
(Table II).
TNF- content was significantly increased in the con-
trol group, which was markedly reduced by INO-1001
Fig 2. Histologic scores for nitrotyrosine (NT), poly(a
apoptosis-inducing factor (AIF) in the different wall
expressed as mean  SD *P  .05 vs sham, †P  .05 vs
Table II. Scores for overall inflammation in the vessel wal
response and neointimal proliferation in the vessel wall laye
Layer Sham
Inflammation Whole vessel wall 0.00
CRP Intima 0.33
Media 1.00
Adventitia 2.33
vWF Intima 0.67
Media 2.67
Adventitia 1.33
TGF-1 Intima 0.88
Media 1.00
Adventitia 2.14
TNF- Intima 0.75
Media 2.25
Adventitia 1.25
CRP, C-reactive protein; vWF, von Willebrand factor; TGF, transforming g
*P  .05 vs sham,
†P  .05 vs control.treatment (Table II).Activation of the peroxynitrite-PARP polymerase
pathway during neointima proliferation after
endarterectomy. To confirm that the effect of INO-1001
on neointima formation was related to the reduction of
PARP activity in our endarterectomy model, activation of
the peroxynitrite-PARP pathway in the vascular wall was
determined.
As shown in Fig 2, immunoreactivity for NT was sig-
nificant in all vessel wall layers of the control group, whereas
sine diphosphate-ribose) (PAR), and nuclear activity of
of sham, control and INO-1001 groups. Values are
rol.
deposition of different markers for inflammatory
10) Control (n  10) INO (n  10)
.00 0.30  0.12* 0.10  0.07†
.58 2.67  1.16* 1.67  0.82
.00 1.33  0.58 1.50  0.55
.53 3.67  2.08 5.33  2.16
.58 3.67  0.58* 2.17  1.33
.16 1.67  0.58 1.33  0.82
.58 2.33  0.58 3.00  1.55
.99 2.86  0.64* 1.00  0.89†
.93 1.63  1.85 0.83  0.75
.86 3.13  1.55 2.67  2.07
.50 7.20  4.38* 2.33  1.86†
.26 3.80  2.28 1.33  0.52
.50 5.20  2.39* 1.33  0.52†
factor; TNF, tumor necrosis factor.deno
layersl and
rs
(n 
 0
 0
 0
 1
 0
 1
 0
 0
 0
 1
 0
 1
 0
rowththe nitrosative stress in all vessel wall sections of the group
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group. In response to surgical vascular injury and nitrosa-
tive stress, the activity of PARP was significantly increased
in the neointima and to less extent in the adventitia of the
control group. An altered pattern was found for the local-
ization of AIF in the neointima of the control group,
whereby a diffuse (mitochondrial) localization of AIF
shifted into a nuclear localization after vascular injury,
consistently with mitochondrial-to-nuclear translocation of
the factor (Figs 2, and 3). Treatment with INO-1001
significantly reduced PAR formation in the whole vessel
wall, and AIF nuclear staining was significantly less in the
intima and media. Fig 3 shows representative stainings for
NT, PAR, and AIF in the different groups.
DISCUSSION
Although evidence shows that reactive oxygen species
and oxidative damage play important roles in restenosis,8,17
few studies have addressed the molecular physiologic
mechanism underlying the oxidative stress hypothesis. In
the present study, we demonstrated that consistent with
nitrosative stress, PARP activity and AIF translocation were
significantly increased in the neointima after endarterec-
tomy. It was previously shown that 14 days after balloon
injury in rat carotid arteries, a significant neointima forma-
tion and PAR activity was detetectable,18 with the maxi-
mum of neointima development after 28 days and a con-
secutive decrease in neointima area.19 Therefore, 21 days
were chosen as follow-up with already existing significant
Fig 3. Representative stainings for nitrotyrosine (NT, br
nuclear translocation of apoptosis-inducing factor (AIF
animals. NT staining was found primarily in the cytosol
was present predominantly in the cell nuclei. AIF staining
of translocation, nevertheless residual staining in the cytos
nuclear AIF immunoreactivity was nearly absent.neointima formation and still ongoing neointima develop-ment and activity of the peroxynitrite-PARP pathway. Neo-
intima formation and inflammatory response after endar-
terectomy were attenuated by treatment with the PARP
inhibitor INO-1001.
PARP is a nuclear enzyme that is activated by DNA
damage induced by reactive oxygen species to participate in
DNA repair.11 Depending on the severity of DNA damage,
three different pathways can be triggered. PARP facilitates
DNA repair and thus cell survival in case of mild DNA
damage. More severe DNA damage induces apoptotic cell
death during which caspases, as main executor enzymes,
inactivate PARP cleaving. Excessive PARP activation de-
plets nicotinamide adenine dinucleotide (NAD) and
adenosine triphosphate stores, blocks apoptosis, and results
in necrosis.12
Another interesting new finding of our study is signif-
icant nuclear activity of the mitochondrial cell death factor
AIF in the proliferating neointima after surgical vascular
injury. This phenomenon is consistent with PARP activa-
tion. AIF appears to be an important factor involved in the
regulation of caspase-independent cell death in neurons20
and cardiac myocytes in vitro during oxidant stress.13 The
in vivo observed release and nuclear translocation of the
mitochondrial AIF in the neointima is regulated by PARP
and reduced by the absence of functional PARP by a
mechanism not yet fully understood.13 One possibility of
how AIF is regulated may be related to a mitochondrially
localized PARP.21 Another possibility may be that the
regulation is mediated by changes in intracellular NAD
, poly(adenosine diphosphate-ribose) (PAR, black), and
blue/black) in sham, control and INO-1001 treated
neointima in the control group, whereas PAR staining
present as well predominantly in the cell nuclei as a result
be observed. After INO-1001 treatment, NT, PAR andown)
, dark
of the
was
ol canconcentrations.13 A third possibility is that a product of
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to-cytoplasmic second messenger, possibly PAR itself—may
signal to the mitochondria, as recent studies demonstrated
the poly(ADP-ribosyl)ation of the cytoplasmatic enzyme
glyceraldehyde-3-phosphate dehydrogenase under condi-
tions of oxidative stress in endothelial cells.22 Clearly, fur-
ther work is necessary to elucidate the interplay of PARP
and AIF during neointimal hyperplasia.
A recent study found the PARP inhibitor PJ34 attenu-
ated neointima formation in balloon-injured rat carotid
artery.18 The dose used in that study was identical to ours.
Their results indicated that pronounced activation of PARP
contributed to neointima proliferation. The significant re-
duction of neointima after pharmacologic PARP inhibition
with PJ34 was attributed to significant reduction of inflam-
matory cell infiltration. In our study, we found also signif-
icant reduction of inflammatory response after treatment
with INO-1001; however, the score for inflammatory cell
infiltration in the control group was quite low. CRP
showed only a trend towards reduced deposition after
INO-1001 treatment. As discussed here and overviewed
elsewhere,11 PARP inhibition acts primarily at the very
distal end of the inflammatory cascade at subcellular levels,
and therefore, CRP is not necessarily reduced significantly
by PARP inhibition. Nevertheless, TNF-, another marker
for inflammation, was significantly reduced by INO-1001
treatment, as is known from the literature.11 PARP is
involved in the regulation of certain cytokines, and in
particular TNF-.11 In that context, INO-1001 inhibits
probably directly the gene expression of TNF-.11
The TGF- system has been identified and character-
ized in both animal models and human lesions as a key
defect of inhibitory systems that regulates atherosclerosis
and other injury-induced hyperplasias such as restenosis.23
TGF- is overexpressed in fibroproliferative vascular le-
sions, allowing a slow but uncontrolled growth while over-
producing extracellular matrix components. We therefore
additionally assessed TGF- as a “restenosis-specific” cyto-
kine marker. We could show that PARP inhibition signifi-
cantly reduces TGF- activation. Whether the observed
reduction in TGF-1 after treatment with INO-1001 in
our study is a primary consequence of PARP inhibition
owing to interrupted cytokine production, as known for
TNF- and interleukin-1,24 or just a secondary phenom-
enon in the context of reduced neointimal hyperplasia
remains to be further investigated.
One can also speculate, that PARP inhibition may have
a direct effect on nitric oxide production, which in turn
influences neointima formation. Failure of nitric oxide re-
lease from the endothelium with normal physiologic stim-
uli, which has been attributed to a defect in the operation of
the endothelial nitric oxide synthase, provides conditions
propitious for leukocyte adhesion, vasospasm, and throm-
bosis, and in addition, promotes increased proliferation of
intimal cells.25 On the other hand, nitric oxide and super-
oxide anions generated by inflammatory cells in atheroscle-
rosis and restenosis react to form cytodestructive peroxyni-
trite radicals (as shown in the present study), potentiallycausing injury to the endothelium and myocytes, and this
may be a factor in apoptosis of cells and in neointima
formation.25
It is well known that generation of peroxynitrite by
overproduction of nitric oxide or superoxide, or both, leads
to a reduced overall bioavailability of nitric oxide.25 It was
shown that PARP inhibition increased nitric oxide bioavail-
ability after balloon injury18 and endothelium-dependent
relaxant ability by PARP was related to modulation of
intracellular NADPH26 as an essential cofactor for nitric
oxide synthase. One can hypothesize that vascular injury
after endarterectomy with increased systemic oxidative
stress27 impairs the regrowing endothelium and reduces
nitric oxide production, which leads to neutrophil infiltra-
tion and further injury as a positive feedback cycle that
might trigger neointimal hyperplasia. Pharmacologic inhi-
bition of PARP, by interrupting this cycle, may both reduce
neutrophil infiltration and oxidant and free radical genera-
tion (and hence, nitrotyrosine staining, a marker of per-
oxynitrite formation, or of nitrosative stress in general), as
seen in our study. We do not have evidence at this point,
however.
CONCLUSION
The current study shows the activation of the
peroxynitrite-PARP pathway during neointima formation af-
ter endarterectomy. From our study, we conclude that inhi-
bition of the pronounced activation of the DNA repair en-
zyme PARP and, consecutively, AIF leads to both reduction
of inflammatory response and neointimal hyperplasia. PARP
inhibition may be a therapeutic strategy for the prevention of
restenosis after surgical vessel reconstruction. Further animal
and human studies are warranted.
We acknowledge the expert assistance of Dr. Marie-
Luise Gross, Department of Pathology, University of Hei-
delberg, Germany, for preparation and interpretation of the
histologic findings.
REFERENCES
1. North American Symptomatic Carotid Endarterectomy Trial Collabo-
rators. Beneficial effect of carotid endarterectomy in symptomatic pa-
tients with high-grade carotid stenosis. N Engl J Med 1991;325:445-
53.
2. Executive Committee for the Asymptomatic Carotid Atherosclerosis
Study. Endarterectomy for asymptomatic carotid artery stenosis. JAMA
1995;273:1421-8.
3. LaMuraglia GM, Brewster DC, Moncure AC, Dorer DJ, Stoner MC,
Trehan SK, et al. Carotid endarterectomy at the millenium: what
interventional therapy must match. Ann Surg 2004;240:535-44.
4. Marinelli G, Chiappini B, Di EusanioM, Di Bartolomeo R, Caldarera I,
Marrozzini C, et al. Bypass grafting with coronary endarterectomy:
immediate and long-term results. J Thorac Cardiovasc Surg 2002;124:
553-60.
5. Harrison D, Griendling KK, Landmesser U, Hornig B, Drexler H. Role
of oxidative stress in atherosclerosis. Am J Cardiol 2003;91:7A-11A.
6. Zalba G, San Jose G, Moreno MU, Fortuno MA, Fortuno A, Beau FJ,
et al. Oxidative stress in arterial hypertension: role of NAD(P)H oxi-
dase. Hypertension 2001;38:1395.
7. Guigliano D, Ceriello A, Paolisso G. Oxidative stress and diabetic
vascular complications. Diabetes Care 1996;19:257-67.
JOURNAL OF VASCULAR SURGERY
April 2006830 Beller et al8. Azevedo LC, Pedro MA, Souza LC, de Souza HP, Janiszewski M, da
Luz PL, et al. Oxidative stress as a signaling mechanism of the vascular
response to injury; the redox hypothesis of restenosis. Cardiovasc Res
2000;47:436-45.
9. Mabley JG, Jagtap P, Peretti M, Getting SJ, Salzman AL, Virag L, et al.
Anti-inflammatory effects of a novel, potent inhibitor of poly(ADP-
ribose) polymerase. Inflamm Res 2001;50:561-9.
10. Martinet W, Knaapen WM, Meyer GR, Herman AG, Kockx MM.
Elevated levels of oxidative DNA damage and DNA repair enzymes in
human atherosclerotic plaques. Circulation 2002;106:927-32.
11. Virag L, Szabo C. The therapeutic potential of poly(ADP-ribose)
polymerase inhibitors. Pharmacol Rev 2002;54:375-429.
12. Soriano FG, Virag L, Jagtap P, Szabo E, Mabley JG, Liaudet L, et al.
Diabetic endothelial dysfunction: the role of poly(ADP-ribose) poly-
merase activation. Nat Med 2001;7:108-13.
13. Chen M, Zsengeller Z, Xiao CY, Szabo C. Mitochondrial-to-nuclear
translocation of apoptosis-inducing factor in cardiac myocytes during
oxidant stress: potential role of poly(ADP-ribose) polymerase-1. Car-
diovasc Res 2004;63:682-8.
14. Jagtap PG, Baloglu E, Southan GJ, Mabley JG, Li H, Zhou J, et al.
Discovery of potent poly(ADP-ribose) polymerase-1 inhibitors from
themodification of indeno1,2-c.isoquinolinone. JMedChem2005;48:
5100-3.
15. Legan E, Sisson JA. Method to denude rat aortic endothelium with
saponin for phosphoinositide analysis in vascular smooth muscle.
J Pharmacol Methods 1990;23:31-9.
16. Hoylaerts MF. Platelet-vessel wall interactions in thrombosis and reste-
nosis role of von Willebrand factor. Verh K Acad Geneeskd Belg
1997;59:161-83.
17. Szocs K, Lassegue B, Sorescu D, Hilenski LL, Valppu L, Couse TL,
et al. Upregulation of Nox-based NAD(P)H oxidases in restenosis after
carotid injury. Arterioscler Thromb Vasc Biol 2002;22:21-7.
18. Zhang C, Yang J, Jennings LK. Attenuation of neointima formation
through the inhibition of DNA repair enzyme PARP-1 in balloon-injured rat carotid artery. Am J Physiol Heart Circ Physiol
2004;287:H659-66.
19. Finn AV, Gold HK, Tang A, Weber DK, Wight TN, Clermont A, et al.
A novel rat model of carotid artery stenting for the understanding of
restenosis in metabolic diseases. J Vasc Res 2002;39:414-25.
20. Cregan SP, Fortin A, MacLaurin JG, Callaghan SM, Cecconi F, Yu SW,
et al. Apoptosis-inducing factor is involved in the regulation of caspase-
independent neuronal cell death. J Cell Biol 2002;158:507-17.
21. Du L, Zhang X, Han YY, Burke NA, Kochanek PM, Watkins SC, et al.
Intra-mitochondrial poly(ADP-ribosylation) contributes to NAD de-
pletion and cell death induced by oxidative stress. J Biol Chem 2003;
278:18426-33.
22. Du X, Matsumura T, Edelstein D, Rosetti L, Zsengeller Z, Szabo C,
et al. Inhibition of GAPDH activity by poly(ADP-ribose) polymerase
activates three major pathways of hyperglycemic damage in endothelial
cells. J Clin Invest 2003;112:986-8.
23. McCaffrey TA. TGF-betas and TGF- receptors in atherosclerosis.
Cytokine Growth Factor Rev 2000;11:103-14.
24. Sharp C, Warren A, Oshima T, Williams L, Li JH, Alexander JS.
PolyADP ribose-polymerase inhibitors prevent the upregulation of
ICAM-1 and E-selectin in response to Th1 cytokine stimulation. In-
flammation 2001;25:157-63.
25. Dusting GJ, Fennessy P, Yin Zl, Gurevich V. Nitric oxide in atheroscle-
rosis: vascular protector or villain? Clin Exp Pharmacol Physiol Suppl
1998;25:S34-41.
26. Jagtap P, Szabo C. Poly(ADP-ribose) polymerase and the therapeutic
effects of its inhibitors. Nat Rev Drug Discov 2005;4:421-40.
27. Mezzetti A, Guglielmi MD, Pierdomenico SD, Costantini F, Cipollone
F, De Cesare D, et al. Increased systemic oxidative stress after elective
endarterectomy: relation to vascular healing and remodeling. Arterio-
scler Thromb Vasc Biol 1999;19:2659-65.Submitted Aug 25, 2005; accepted Nov 12, 2005.
